

Synthesis and Utility of 2-(Benzoyloxyimino)-2-deoxy- α -D-*lyxo*-hexopyranosyl Bromide as a Novel α -D-Talosaminide Building Block

Eisuke KAJI,* Yumiko OSA, Keiko TAKAHASHI, and Shonosuke ZEN

School of Pharmaceutical Sciences, Kitasato University, Shirokane 5-9-1, Minato-ku, Tokyo 108, Japan.

Received June 12, 1995; accepted August 31, 1995

A novel α -D-talosaminyl donor, 2-(benzoyloxyimino)-2-deoxy- α -D-*lyxo*-hexopyranosyl bromide has been synthesized in a total yield of 32% over 6 steps from D-galactose. The utility of the donor was evaluated for the elaboration of α -D-TalNAc-(1 $\rightarrow$ 6)- α -D-Gal, α -D-TalNAc-(1 $\rightarrow$ 6)- α -D-Glc, and α -D-TalNAc-(1 $\rightarrow$ 3)-L-serine derivatives by a simple 3-step sequence, comprising α -selective glycosylation of appropriately protected acceptors of D-galactose, D-glucose, and L-serine, *talo*-selective hydroboration of the oxyimino function to an amino group, and *N*-acetylation.

Key words 2-ulose oxime; TalNAc building block; α -D-talosaminide; glycosylation; hydroboration

2-Amino-2-deoxy-D-talose (**1**, D-talosamine) has been found as a constituent of ovine¹⁾ and bovine²⁾ cartilage, while 2-amino-2,6-dideoxy-L-talose (**2**, pneumosamine) is a component of the capsular polysaccharide from *Streptococcus pneumoniae* type 5.³⁾ The availability of amino sugars from natural sources is limited, and hence, considerable efforts have been made to achieve synthetic access to **1** and **2**,⁴⁾ for structural studies on natural talosamine-containing oligosaccharides.

In our continuing studies to develop a synthetic vaccine based on the bacterial capsular polysaccharides⁵⁾ and lipopolysaccharides,⁶⁾ we required a practical synthetic method of *N*-acetyl-D-talosamine (D-TalNAc) for the construction of antigenic oligosaccharides, as well as chemically modified forms, elicited from the pneumococcal capsular polysaccharides.

The usual access to D-talosamine derivatives utilizes Kuhn's amino nitrile procedure,⁷⁾ a configurational inversion of 2-amino-2-deoxy-D-idose at C-3,⁸⁾ and a reduction of 2-(oxyimino)-2-deoxyglycosides with LiBH₄-Me₃SiCl.⁹⁾ However, neither of the former two approaches meets practical preparative criteria, inasmuch as they entail very low stereoselectivity⁷⁾ or multistep transformations from D-galactose.⁸⁾ The last approach, *i.e.*, the oxyiminoglycosyl procedure, appears to be most promising with respect to facility and stereoselectivity,⁹⁾ but the accessibility of the intermediary α -D-oxyiminoglycosides is rather poor, requiring Lemieux's nitrosoglycal method¹⁰⁾ or Stevens' method¹¹⁾ *via* 2-ulose intermediates for the preparation of even simple alkyl 2-deoxy-2-(methoxyimino)- α -D-*lyxo*-hexopyranosides.

We here disclose a general, straightforward methodology using a versatile α -D-TalNAc donor, namely 2-(benzoyloxyimino)-2-deoxy- α -D-*lyxo*-hexopyranosyl bromide (**7**), which allows glycosylation of some glycosyl acceptors and subsequent reduction of the 2-benzoyloxyimino function to a 2-amino group, yielding α -D-TalNAc-containing oligosaccharides in a stereoselective fashion.

Results and Discussion

Preparations of 2-(Benzoyloxyimino)-2-deoxy-glycosyl Bromide (7**) and Diethyldithiocarbamate (**8**)** Based on our previous studies,¹²⁾ 2-(benzoyloxyimino)-2-deoxy- α -

D-*erythro*-hexopyranosyl bromide can be utilized for practical assembly of oligosaccharides containing *N*-acetyl- β -D-mannosamine¹³⁾ and its α -D-analogue⁵⁾ associated with *Streptococcus pneumoniae* type 19F capsular polysaccharide. Accordingly, an α -D-TalNAc sugar unit may be formed stereoselectively from 2-(benzoyloxyimino)-2-deoxy-glycosyl bromide with α -D-*lyxo*-configuration, which should be readily accessible by a simple, 3-step conversion of a 2-hydroxy-D-galactal **4**. At first, the galactal **4** was prepared in 70% yield from 2,3,4,6-tetra-*O*-benzoyl- α -D-galactopyranosyl bromide (**3**) by the use of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in *N,N*-dimethylformamide (DMF). Oximation of **4** with excess hydroxylamine hydrochloride in pyridine afforded the 1,5-anhydro-D-tagatose oxime **5** in 73% yield. Subsequent *O*-benzoylation of **5** with benzoyl chloride in pyridine gave the *O*-benzoylated oxime **6** in 81% yield. The concluding photobromination with *N*-bromosuccinimide (NBS) proceeded smoothly to furnish the desired 2-(benzoyloxyimino)-2-deoxy- α -D-*lyxo*-hexopyranosyl bromide **7** in 90% yield. Conventional dithiocarbamoylation of **7** with sodium *N,N*-diethyldithiocarbamate readily gave an alternative TalNAc donor **8** in 84% yield. Both donors were stable, crystalline substances storable in a refrigerator for months without decomposition.

Syntheses of α -D-TalNAc-(1 $\rightarrow$ 6)-D-Gal (12a**), α -D-TalNAc-(1 $\rightarrow$ 6)-D-Glc (**12b**), and α -D-TalNAc-(1 $\rightarrow$ 3)-L-serine (**12c**) Derivatives** The utility of the donors **7** and **8** was first evaluated for stereoselective glycosylation of some glycosyl acceptors with a free hydroxyl group based on D-galactose (**9a**),¹⁴⁾ D-glucose (**9b**),¹⁵⁾ and L-serine (**9c**),¹⁶⁾ and then for stereoselective reduction of the 2-benzoyloxyimino function to a 2-amino group. The results of glycosylation of **9** with the donors **7** and **8** under several reaction conditions are summarized in Table 1.

Silver triflate (AgOTf)-promoted glycosylation of **9a** with the bromide **7** in CH₂Cl₂ afforded good α -selectivity (run 1, α : β =6:1, 52% yield). Changing the solvent to CH₃CN or dioxane resulted in no superiority over CH₂Cl₂ (runs 2 and 3). Application of an insoluble silver catalyst such as Ag₂CO₃ resulted in only partial predominance of the β -anomer **11a** (run 4). Other acceptors (**9b** and **9c**) were similarly glycosylated with the bromide

* To whom correspondence should be addressed.




Chart 1

Table 1. Glycosylation of Alcohol Components (9) with Tri-*O*-benzoyl-2-(benzoyloxyimino)-2-deoxy-*D*-lyxo-hexopyranosyl Donors (7 and 8)

Run	Donor	Acceptor	Promoter	Solvent	Conditions		Products 10:11 ^{a)}	Total yield (%)
					Temperature	Time (h)		
1	7	9a	AgOTf/TMU	CH ₂ Cl ₂	r.t.	20	6:1	52
2	7	9a	AgOTf/TMU	CH ₃ CN	r.t.	20	3:2	27
3	7	9a	AgOTf/TMU	Dioxane	r.t.	20	2:1	10
4	7	9a	AgCO ₃ /I ₂	CH ₂ Cl ₂	r.t.	48	2:3	55
5	7	9b	AgOTf/TMU	CH ₂ Cl ₂	r.t.	20	5:1	42
6	7	9c	AgOTf/TMU	CH ₂ Cl ₂	r.t.	20	5:1 ^{b)}	59
7	8	9c	MeOTf/DTBP ^{c)}	CH ₂ Cl ₂	r.t.	2	2:1 ^{b)}	47

^{a)} The 10:11 ratio was estimated by ¹H-NMR integration of the respective anomeric protons. ^{b)} The 10:11 ratio was determined from the isolated yields of the products. ^{c)} DTBP designates 2,6-di-*tert*-butylpyridine. r.t. = room temperature.

7, promoted by AgOTf/1,3,3-tetramethylurea (TMU), to give the α -anomers **10b** and **10c** in preference to the β -anomers (**11b** and **11c**) (runs 5 and 6). On the other hand, the use of glycosyl diethyldithiocarbamate **8** proved to afford less selectivity and efficiency than the bromide **7** (run 7).

The α -configuration of **10** was confirmed on the basis of the ¹H-NMR spectra, in which the signals of the anomeric protons (H-1') invariably appeared at lower field (δ : 6.35, 6.35, and 6.23 for **10a**, **10b**, and **10c**, respectively), whereas the corresponding β -glycosides exclusively showed their anomeric proton signals at relatively higher field (δ : 5.97, 6.09, and 5.59 for **11a**, **11b**, and **11c**, respectively). Similar tendencies have been observed with respect to the anomeric chemical shifts of analogous compounds possessing a 2-benzoyloxyimino group.^{17,18)} In the ¹³C-NMR spectra of **10** and **11**, the C-1' signals appeared at δ : 91.87–92.35 (**10**) and 99.83 (**11c**), sup-

porting the anomeric configurations described above.

Another key step for the construction of α -D-TalNAc is the stereocontrolled transformation of the benzoyloxyimino function into the *talo*-oriented acetamido group. We showed previously that the reduction of 2-(benzoyloxyimino)- α -D-glycosides by hydroboration is dependent on the kind of aglycons employed, yielding either α -D-mannosaminide⁵⁾ or α -D-glucosaminide.^{17,19)} Although the mechanism of the stereoselectivity remains to be resolved, the present stereochemical outcome is such that 2-(benzoyloxyimino)-2-deoxy- α -D-*erythro*-hexopyranosides with a simple alkyl or benzyl aglycon are transformed into α -D-glucosaminides,^{17–19)} and the analogues with a sterically hindered glycosyl aglycon⁵⁾ gave rise to α -D-mannosaminides. Accordingly, the reduction of the disaccharides **10a** and **10b** by hydroboration would be expected to form α -D-talosaminides (**12**) rather than α -D-galactosaminides (**13**).




Chart 2

In fact, hydroboration of **10a** and **10b** with a twelve molar excess of borane tetrahydrofuran (THF) complex in THF followed by *N*-acetylation (Ac_2O /pyridine) led to the desired 2-acetamido-2-deoxy- α -D-talosaminides **12a** and **12b** in yields of around 40%. Although the reduction of **10**→**12** is still unsatisfactory with respect to the efficiency, the yields were improved by recycling the unreacted starting materials (31% and 51% recoveries of **10a** and **10b**, respectively); in this way, the overall yield for the conversion **10**→**12** amounted to 57% for **12a** and 60% for **12b** after one recycling process. On the other hand, the L-serine glycoside **10c** was reduced to form a mixture of α -D-talosaminide **12c** and α -D-galactosaminide **13** in a ratio of 4:3.

At this stage we have no decisive evidence that the *talo* selectivity is elicited by the stereochemical demand of the sugar aglycons of **10a** and **10b** as compared with the amino acid aglycon of **10c**. Hence, a variety of 2-(benzo-

xyloxyimino)-2-deoxy- α -D-glycosides of type **10** having various kinds of aglycons are being prepared for the elucidation of the reduction mechanism of the 2-acyloxyimino group. The results will be reported elsewhere.

The α -D-*talo*-configuration of the amino sugar moiety of **12** was determined from the coupling constants $J_{1',2'}$ and $J_{2',3'}$ of ca. 2.0–3.0 and 4.0–5.0 Hz, which are in good agreement with those reported for α -D-TalNAc derivatives.⁹⁾ In contrast, the α -D-*galacto*-configuration of **13** was evidenced by the $J_{1',2'}$ and $J_{2',3'}$ values of 4.0 and 11.0 Hz, respectively.

In summation, a practical, straightforward reaction sequence has been developed for generating a useful α -D-TalNAc donor, 2-(benzoyloxyimino)-2-deoxy- α -D-*lyxo*-hexopyranosyl bromide **7**, in an overall yield of 32% for 6 steps from D-galactose. Its utility for assembly of α -D-TalNAc-containing oligosaccharides was demonstrated by α -glycosidation of **7**, followed by reduction of

the oxyimino function in a stereoselective manner. This approach will be applied to the synthesis of a variety of other α -D-TalNAc-containing oligosaccharides of biological significance.

Experimental

Melting points are uncorrected values obtained on a Yanagimoto micro melting point apparatus or Yamato MP-1 apparatus. Spectral measurements- $[\alpha]_D$: Jasco DIP-150; ^1H - and ^{13}C -NMR: Varian VXR-300 or XL-400; MS: JMS D-100 instrument. FAB-MS were measured with a PEG 400 or *meta*-nitrobenzoic acid (*m*-NBA) matrix in acetone. TLC: Merck Silica Gel F₂₅₄ plastic sheets were used to monitor the reactions and to ascertain the purity of the products; solvent systems are given individually and were the same for TLC and column chromatography. Spots were visualized by UV light (254 nm) or by charring with 10% aqueous H_2SO_4 . Column chromatography: Merck Silica gel 60 (70–230 mesh).

1,5-Anhydro-2,3,4,6-tetra-*O*-benzoyl- β -lyxo-hex-1-enitol (4) 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 0.40 ml, 2.7 mmol) was added dropwise to an ice-cooled stirred solution of 2,3,4,6-tetra-*O*-benzoyl- α -D-galactopyranosyl bromide²⁰ (3) (1.0 g, 1.5 mmol) in DMF (1.0 ml). The mixture was left standing at room temperature for 3 h and then poured into ice-water (4 ml). The precipitates were collected, dried (P_2O_5), and purified by elution from a silica-gel column with MeC_6H_5 –AcOEt (10:1). The major fraction was concentrated and crystallized from MeOH– H_2O to afford 610 mg (70%) of **4** as colorless crystals, mp 62–64 °C, $[\alpha]_D^{25} + 36.6^\circ$ ($c=1.0$, CHCl_3). ^1H -NMR (300 MHz, CDCl_3) δ : 4.61 (1H, dd, H-6a), 4.84 (1H, ddd, H-5), 4.91 (1H, dd, H-6b), 6.05 (1H, dd, H-4), 6.39 (1H, d, H-3), 6.96 (1H, s, H-1), 7.24–8.15 (aromatic H); $J_{3,4}=5.0$, $J_{4,5}=2.0$, $J_{5,6a}=4.0$, $J_{5,6b}=7.5$, $J_{6a,6b}=11.0$ Hz. ^{13}C -NMR (75 MHz, CDCl_3) δ : 62.12 (C-6), 64.72 (C-3), 65.05 (C-4), 73.59 (C-5), 127.59 (C-2), 128.3–133.5 (C_6H_5), 139.49 (C-1), 165.23, 165.32, 165.59, 166.19 (COC_6H_5). FAB-MS m/z : 579 ($\text{M}+\text{H}$)⁺, 601 ($\text{M}+\text{Na}+\text{H}$)⁺. Anal. Calcd for $\text{C}_{34}\text{H}_{26}\text{O}_9$: C, 70.58; H, 4.53. Found: C, 70.56; H, 4.48.

Oxime of 1,5-Anhydro-3,4,6-tri-*O*-benzoyl-D-tagatose (5) A mixture of the galactal **4** (116 mg, 0.20 mmol) and hydroxylamine hydrochloride (76 mg, 1.1 mol) in dry pyridine (1.4 ml) was stirred at 40 °C for 20 h. After concentration of the mixture *in vacuo*, the residue was diluted with CH_2Cl_2 (15 ml) and washed with H_2O (15 ml). The organic phase was consecutively washed with 1 M HCl (15 ml), H_2O (15 ml), 5% aqueous NaHCO_3 (15 ml), and H_2O (3 $\times$ 15 ml). Drying (Na_2SO_4) and concentration *in vacuo* gave a residue, which was purified by elution from a silica-gel column with MeC_6H_5 –AcOEt (10:1) to give 70.9 mg (73%) of **5** as a colorless syrup, $[\alpha]_D^{26} - 11.9^\circ$ ($c=1.0$, CHCl_3). ^1H -NMR (300 MHz, CDCl_3) δ : 4.07 (1H, d, H_R-1), 4.33 (1H, m, H-5), 4.40 (1H, m, H-6a), 4.61 (1H, m, H-6b), 5.35 (1H, d, H_S-1), 6.01 (1H, dd, H-4), 6.03 (1H, d, H-3), 7.12–8.14 (aromatic H), 8.23 (1H, s, NOH); $J_{1,1}=15.0$, $J_{3,4}=3.5$, $J_{4,5}=1.0$, $J_{5,6a}=4.5$, $J_{5,6b}=6.0$, $J_{6a,6b}=10.0$ Hz. ^{13}C -NMR (75 MHz, CDCl_3) δ : 60.89 (C-1), 62.41 (C-6), 69.22 (C-3), 69.48 (C-4), 74.69 (C-5), 128.2–133.6 (C_6H_5), 149.40 (C-2), 165.05, 165.71, 166.12 (COC_6H_5). FAB-MS m/z : 490 (M)⁺, 512 ($\text{M}+\text{Na}-\text{H}$)⁺.

Benzoyloxime of 1,5-Anhydro-3,4,6-tri-*O*-benzoyl-D-tagatose (6) Benzoyl chloride (1.2 ml, 10.2 mmol) was added dropwise to an ice-cooled, stirred solution of the oxime **5** (500 mg, 1.02 mmol) in dry pyridine (6.0 ml). The mixture was stirred at ambient temperature for 4 h, poured into ice- H_2O (100 ml), and extracted with CH_2Cl_2 (40 ml). The organic phase was washed with 1 M HCl (40 ml), 5% aqueous NaHCO_3 (40 ml), and H_2O (3 $\times$ 40 ml). Drying (Na_2SO_4) and concentration *in vacuo* gave a residue, which was eluted from a silica-gel column with MeC_6H_5 –AcOEt (10:1). Evaporation of the eluate containing **6** (TLC) and trituration of the residue with Et₂O–pentane provided 490 mg (81%) of **6** as a colorless powder, mp 67–72 °C, $[\alpha]_D^{25} - 8.8^\circ$ ($c=1.0$, CHCl_3). ^1H -NMR (300 MHz, CDCl_3) δ : 4.37 (1H, d, H_R-1), 4.39 (1H, dd, H-6a), 4.48 (1H, m, H-5), 4.69 (1H, dd, H-6b), 5.48 (1H, d, H_S-1), 6.14 (1H, dd, H-4), 6.23 (1H, d, H-3), 7.2–8.2 (aromatic H); $J_{1,1}=15.0$, $J_{3,4}=3.5$, $J_{4,5}=1.0$, $J_{5,6a}=5.0$, $J_{5,6b}=6.5$, $J_{6a,6b}=10.0$ Hz. ^{13}C -NMR (75 MHz, CDCl_3) δ : 62.10 (C-6), 62.34 (C-1), 69.26 (C-3), 69.49 (C-4), 74.98 (C-5), 128–134 (C_6H_5), 158.30 (C-2), 165.0, 165.5, 166.0 (COC_6H_5). FAB-MS m/z : 594 (M)⁺, 616 ($\text{M}+\text{Na}-\text{H}$)⁺. Anal. Calcd for $\text{C}_{34}\text{H}_{27}\text{NO}_9$: C, 68.80; H, 4.59; N, 2.36. Found: C, 68.61; H, 4.32; N, 2.64.

3,4,6-Tri-*O*-benzoyl-2-(benzoyloxymino)-2-deoxy- α -D-lyxo-hexo-

pyranosyl Bromide (7) A mixture of the benzoyloxime **6** (276 mg, 0.47 mmol) and *N*-bromosuccinimide (126 mg, 0.71 mmol) in dry CCl_4 (10 ml) was irradiated with a 250 W tungsten lamp such that gentle reflux was effected. After 30 min the resulting yellowish solution was cooled (0 °C), the precipitate (succinimide) was filtered off, and the filtrate was evaporated to dryness. The residue was partitioned between CH_2Cl_2 (30 ml) and H_2O (30 ml). The organic phase was washed with H_2O (2 $\times$ 25 ml), dried (Na_2SO_4), and concentrated *in vacuo* to give a syrup. Crystallization from Et₂O–pentane furnished 285 mg (90%) of **7** as a pale yellow powder, mp 68–72 °C, $[\alpha]_D^{20} + 239^\circ$ ($c=1.2$, CHCl_3). ^1H -NMR (300 MHz, CDCl_3) δ : 4.48 (1H, dd, H-6a), 4.65 (1H, dd, H-6b), 4.96 (1H, ddd, H-5), 6.20 (1H, dd, H-4), 6.61 (1H, d, H-3), 7.72 (1H, s, H-1), 7.2–8.2 (aromatic H); $J_{3,4}=3.5$, $J_{4,5}=1.0$, $J_{5,6a}=6.5$, $J_{5,6b}=7.0$, $J_{6a,6b}=12.0$ Hz. ^{13}C -NMR (75 MHz, CDCl_3) δ : 61.57 (C-6), 66.42 (C-3), 68.22 (C-4), 72.17 (C-5), 74.03 (C-1), 128–134 (C_6H_5), 155.0 (C-2), 165.0, 165.5, 166.0 (COC_6H_5). FAB-MS m/z : 672 (M)⁺. Anal. Calcd for $\text{C}_{34}\text{H}_{26}\text{BrNO}_9$: C, 60.71; H, 3.87; N, 2.08. Found: C, 61.13; H, 4.08; N, 2.15.

3,4,6-Tri-*O*-benzoyl-2-(benzoyloxymino)-2-deoxy- β -D-lyxo-hexopyranosyl *N,N*-Diethyldithiocarbamate (8) A mixture of sodium *N,N*-diethyldithiocarbamate (450 mg, 2.0 mmol) and molecular sieves (3A, 1.0 g) in dry acetone (2.0 ml) was stirred at room temperature for 1 h. 2-(Benzoyloxymino)-2-deoxyglycosyl bromide **7** (1.33 g, 2.0 mmol) was then added, and the mixture was further stirred for 0.5 h, filtered through a pad of Celite, and concentrated to dryness. The residue was diluted with CH_2Cl_2 (30 ml) and washed with H_2O (3 $\times$ 10 ml). Drying and concentration to dryness gave a syrup, which was eluted from a silica-gel column with MeC_6H_5 –AcOEt (10:1). The major fraction was concentrated and crystallized from Et₂O–pentane to afford 1.24 g (84%) of **8** as colorless crystals, mp 165–169 °C, $[\alpha]_D^{25} - 15.5^\circ$ ($c=0.83$, CHCl_3). ^1H -NMR (300 MHz, CDCl_3) δ : 1.18, 1.25 (3H each, t, CH_2CH_3), 3.64, 3.74 (2H, q, CH_2CH_3), 3.98, 4.05 (2H, q, CH_2CH_3), 4.68 (1H, dd, H-6a), 4.85 (1H, dd, H-5), 4.87 (1H, dd, H-6b), 6.24 (1H, dd, H-4), 6.54 (1H, d, H-3); $J_{3,4}=4.0$, $J_{4,5}=5.0$, $J_{5,6a}=3.0$, $J_{5,6b}=7.0$, $J_{6a,6b}=7.5$ Hz. ^{13}C -NMR (75 MHz, CDCl_3) δ : 11.38, 12.62 (2 $\times$ CH_2CH_3), 47.08, 50.73 (2 $\times$ CH_2CH_3), 62.08 (C-6), 67.88 (C-4), 68.17 (C-3), 74.15 (C-5), 81.65 (C-1), 158.35 (C-2), 190.46 (C=S). FAB-MS m/z : 741 ($\text{M}+\text{H}$)⁺, 763 ($\text{M}+\text{Na}$)⁺. Anal. Calcd for $\text{C}_{39}\text{H}_{36}\text{N}_2\text{O}_9\text{S}_2$: C, 63.23; H, 4.90; N, 3.78. Found: C, 62.91; H, 4.66; N, 3.94.

6-*O*-[3,4,6-Tri-*O*-benzoyl-2-(benzoyloxymino)-2-deoxy- α -D-lyxo-hexopyranosyl]-1,2:3,4-di-*O*-isopropylidene- α -D-galactopyranose (10a) 1,1,3,3-Tetramethylurea (TMU) (0.1 ml, 0.8 mmol) was added to a mixture of 1,2:3,4-di-*O*-isopropylidene- α -D-galactopyranose **9a**¹⁴ (135 mg, 0.52 mmol) AgOTf (134 mg, 0.52 mmol), and the glycosyl bromide **7** (270 mg, 0.4 mmol) in dry CH_2Cl_2 (4 ml), containing powdered molecular sieves (3A, 200 mg). The mixture was stirred in the dark at room temperature for 20 h, then diluted with CH_2Cl_2 (30 ml), and filtered through a pad of Celite. The filtrate was washed successively with 5% aqueous NaHCO_3 (30 ml) and H_2O (3 $\times$ 30 ml), then dried (Na_2SO_4), and the solvent was removed *in vacuo* to give a residue, which was eluted from a silica-gel column with MeC_6H_5 –AcOEt (5:1). The major fraction was concentrated to provide 177 mg (52%) of **10a** as a yellowish syrup, slightly contaminated with the unconcentrated β -anomer **11a** (**10a**: **11a** = 6:1, estimated by ^1H -NMR, $[\alpha]_D^{18} + 10.5^\circ$ ($c=1.0$, CHCl_3). ^1H -NMR (300 MHz, CDCl_3) δ : 1.20, 1.29, 1.34, 1.56 (3H each, s, 2 $\times$ CMe_2), 4.00 (2H, dd, H-6a, 6b), 4.09 (1H, ddd, H-5), 4.25 (1H, dd, H-4), 4.32 (1H, dd, H-2), 4.40 (1H, dd, H-6'a), 4.60 (1H, dd, H-3), 4.63 (1H, dd, H-6'b), 4.96 (1H, ddd, H-5'), 5.53 (1H, d, H-1), 5.97 (1H, s, β -H-1'), 6.15 (1H, dd, H-4'), 6.35 (1H, s, α -H-1'), 6.41 (1H, d, H-3' of the β -anomer), 6.44 (1H, d, H-3' of the α -anomer), 7.2–8.2 (aromatic H); $J_{1,2}=5.0$, $J_{2,3}=2.5$, $J_{3,4}=8.0$, $J_{4,5}=2.0$, $J_{5,6a}=J_{5,6b}=6.0$, $J_{6a,6b}=8.0$, $J_{3',4'}=3.0$, $J_{4',5'}=1.0$, $J_{5',6'a}=J_{5',6'b}=6.5$, $J_{6'a,6'b}=11.0$ Hz. ^{13}C -NMR (75 MHz, CDCl_3) δ : 24.31, 24.86, 25.88, 26.11 (4 $\times$ CH_3), 62.27 (C-6), 66.59 (C-5), 67.60 (C-3'), 67.70 (C-4'), 67.87 (C-5'), 67.93 (C-6), 70.46 (C-2), 70.65 (C-3), 70.94 (C-4), 91.87 (C-1'), 96.32 (C-1), 108.80, 109.42 (2 $\times$ CCH_3), 128.3–133.5 (C_6H_5), 156.26 (C-2'), 162.64, 165.02, 165.82, 165.94 (4 $\times$ COC_6H_5). FAB-MS m/z : 874 ($\text{M}+\text{H}$)⁺, 957 ($\text{M}+\text{DEA}+\text{H}$)⁺.

Methyl 6-*O*-[3,4,6-Tri-*O*-benzoyl-2-(benzoyloxymino)-2-deoxy- α -D-lyxo-hexopyranosyl]-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (10b) Methyl 2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (**9b**)¹⁵ (72.5 mg, 0.13 mmol) was glycosylated with the glycosyl bromide **7** (67.2 mg, 0.10 mmol) as described for **10a**. After general work-up the product was purified by column chromatography on silica gel with MeC_6H_5 –AcOEt (10:1) to

afford 44.3 mg (42%) of a 5:1 mixture of **10b** and **11b** as a yellowish syrup, $[\alpha]_D^{25} + 91.1^\circ$ ($c=0.8$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) of **10b**: δ : 3.31 (3H, s, CH_3), 3.32 (1H, dd, H-2), 3.40 (3H, s, CH_3 of **11b**), 3.42 (1H, dd, H-4), 3.77 (1H, br d, H-5), *ca.* 3.8 (1H, m, H-3), 3.91 (1H, dd, H-6a), 3.94 (1H, dd, H-6b), 4.37 (1H, d, H-1), 4.43 (1H, dd, H-6'a), 4.55 (1H, dd, H-6'b), 4.6—5.0 ($3 \times \text{PhCH}_2$), 4.88 (1H, ddd, H-5'), 6.07 (1H, dd, H-4'), 6.09 (1H, s, H-1' of **11b**), 6.33 (1H, d, H-3'), 6.35 (1H, s, H-1'), 7.2—8.2 (aromatic H); $J_{1,2}=3.5$, $J_{2,3}=J_{3,4}=J_{4,5}=J_{5,6b}=9.0$, $J_{5,6a}=4.5$, $J_{6a,6b}=10.0$, $J_{3',4'}=3.5$, $J_{4',5'}=1.0$, $J_{5',6'a}=J_{5',6'b}=5.0$ Hz. $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) of **10b**: δ : 55.20 (OCH_3), 66.84 (C-6), 67.57 (C-3'), 67.82 (C-6'), 70.02 (C-5), 70.67 (C-4'), 63.24 (C-5'), 74.96, 75.53 ($2 \times \text{PhCH}_2$), 77.24 (C-4), 80.21 (C-2), 81.91 (C-3), 91.95 (C-1'), 97.79 (C-4), 127—130, 134, 138 (C_6H_5), 157.2 (C-2'), 165—166 (COC_6H_5). FAB-MS m/z : 1055 (M^+), 1079 ($\text{M} + \text{Na} + \text{H}^+$).

O³-(3,4,6-Tri-O-benzoyl-2-(benzoyloxyimino)-2-deoxy- α -D-lyxohexopyranosyl)-N-benzoyloxycarbonyl-L-serine Benzyl Ester (10c) Method A (Use of the Glycosyl Bromide 7): *N*-Benzoyloxycarbonyl-L-serine benzyl ester **9c**¹⁶⁾ (41.1 mg, 0.125 mmol) was glycosylated with the glycosyl bromide **7** (67.2 mg, 0.10 mmol) in dry CH_2Cl_2 (1 ml) as described for **10a**. After general work-up, the crude syrupy product was eluted from a silica-gel column with MeC_6H_5 -AcOEt (5:1). A faster-eluting fraction was concentrated to afford 45.6 mg (50%) of **10c**, and a slower-eluting one gave 8.7 mg (9%) of **11c**, each as a colorless syrup. **10c**: $[\alpha]_D^{25} + 65.2^\circ$ ($c=0.6$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 4.17, 4.28 (1H each, dd, H-3), 4.52—4.59 (2H, m, H-5', 6'), 4.69 (1H, m, H-2), 5.91 (1H, d, NH), 5.97 (1H, dd, H-4'), 6.18 (1H, d, H-3'), 6.23 (1H, s, H-1'); $J_{3',4'}=3.5$, $J_{4',5'}=1.0$, $J_{2,\text{NH}}=7.5$ Hz. $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 54.44 (C-2), 62.33 (C-6'), 67.44 (C-3'), 69.91 (C-3), 70.25 (C-4'), 77.20 (C-5'), 92.35 (C-1'), 155.41 (C-2'), 165.7 (C-1). FAB-MS m/z : 921 ($\text{M} + \text{H}^+$), 943 ($\text{M} + \text{Na}^+$).

11c: $[\alpha]_D^{25} + 29.5^\circ$ ($c=1.0$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 4.17, 4.26 (1H each, dd, H-3), 4.34 (1H, dd, H-6'a), 4.54 (1H, dd, H-6'b), 4.59 (1H, ddd, H-5'), 4.71 (1H, td, H-5), 5.11, 5.15, 5.22, 5.33 (1H each, d, CH_2Ph), 5.59 (1H, s, H-1'), 5.89 (1H, dd, H-4'), 5.93 (1H, d, NH), 6.07 (1H, d, H-3'); $J_{3',4'}=3.0$, $J_{4',5'}=1.0$, $J_{5',6'a}=5.0$, $J_{5',6'b}=6.0$, $J_{6'a,6'b}=10.0$, $J_{2,\text{NH}}=8.0$, $J_{2,3a}=3.0$, $J_{2,3b}=4.0$, $J_{3a,3b}=10.0$ Hz. $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 54.48 (C-2), 62.17 (C-6'), 67.19, 67.86 (CH_2Ph), 68.96 (C-5'), 69.77 (C-3), 70.47 (C-3'), 71.12 (C-4'), 99.83 (C-1'), 155.04 (C-2'), 165.55 (C-1). FAB-MS m/z : 921 ($\text{M} + \text{H}^+$), 943 ($\text{M} + \text{Na}^+$).

Method B (Use of the Glycosyl Carbamate 8): Methyl triflate (34.4 μl , 0.3 mmol) and 2,6-di-*tert*-butylpyridine (DTBP) (13.6 μl , 60.7 μmol) were added to a stirred solution of the carbamate **8** (50 mg, 67.5 μmol) and the suitably protected L-serine **9c** (22.2 mg, 67.5 μmol) in dry CH_2Cl_2 (1 ml) with molecular sieves (3 A, 100 mg). The mixture was stirred at room temperature for 2 h. Triethylamine (2 μl , 9.68 μmol) was added to the mixture, which was then filtered through a pad of Celite. The filtrate was evaporated to dryness and the residue was eluted from a silica-gel column with MeC_6H_5 -AcOEt (5:1) to give 20.3 mg (33%) of **10c** and 8.7 mg (14%) of **11c**.

6-O-(2-Acetamido-3,4,6-tri-O-benzoyl-2-deoxy- α -D-talopyranosyl)-1,2,3,4-di-O-isopropylidene- α -D-galactopyranose (12a) A 1 M solution of $\text{BH}_3 \cdot \text{THF}$ complex in THF (4.1 ml) was added dropwise to a solution of the disaccharide **10a** (174 mg, 0.204 mmol) in THF (4 ml) at -10°C under an atmosphere of N_2 . The mixture was stirred at this temperature for 0.5 h, and then allowed to warm to room temperature. Stirring was continued for a further 2 h, then excess reductant was quenched with MeOH (3 ml). *N*-Acetylation was effected by stirring the mixture with Ac_2O (1 ml) at ambient temperature for 1 h. The resulting mixture was passed through a basic resin (Amberlite IR-45), which was washed with MeOH. The eluate was concentrated *in vacuo* and the residue was purified by elution from a silica-gel column with CHCl_3 -AcOEt (1:1). The major fractions were concentrated to give 64.9 mg (41%) of **12a** and 67.5 mg (39% recovery) of the unreacted starting material. **12a**: a colorless syrup, $[\alpha]_D^{25} + 26.9^\circ$ ($c=1.1$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.31, 1.34, 1.39, 1.56 (3H each, s, $4 \times \text{CH}_3$), 1.86 (3H, s, COCH_3), 3.81 (1H, dd, H-6a), 3.89 (1H, dd, H-6b), 4.04 (1H, ddd, H-5), 4.28 (1H, dd, H-4), 4.31 (1H, dd, H-2), 4.36 (1H, dd, H-6'a), 4.51 (1H, dd, H-6'b), 4.62 (1H, dd, H-3), 4.69 (1H, dd, H-2'), 4.75 (1H, ddd, H-5'), 5.02 (1H, d, H-1'), 5.52 (1H, d, H-1), 5.69 (1H, dd, H-3'), 5.96 (1H, dd, H-4'), 6.51 (1H, d, NH); $J_{1,2}=5.1$, $J_{2,3}=2.3$, $J_{3,4}=7.2$, $J_{4,5}=2.0$, $J_{5,6a}=J_{5,6b}=6.0$, $J_{6a,6b}=9.8$, $J_{1',2'}=3.0$, $J_{2',\text{NH}}=9.5$, $J_{2',3'}=5.0$, $J_{3',4'}=3.5$, $J_{4',5'}=1.0$, $J_{5',6'a}=J_{5',6'b}=6.5$, $J_{6'a,6'b}=11.0$ Hz. FAB-MS m/z : 775 ($\text{M} + \text{H}^+$), 798 ($\text{M} + \text{Na}^+$).

Methyl 6-O-(2-Acetamido-3,4,6-tri-O-benzoyl-2-deoxy- α -D-talopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (12b) A solution of the disaccharide **10b** (44.2 mg, 0.042 mmol) in dry THF (0.84 ml) was treated with a 1 M solution of $\text{BH}_3 \cdot \text{THF}$ complex in THF (0.84 ml) as described for **10a** $\rightarrow$ **12a**. Termination with MeOH (0.6 ml) and subsequent *N*-acetylation with Ac_2O (0.2 ml) followed by processing of the mixture as described for **12a** gave a syrup, which was eluted from a silica-gel column with CHCl_3 -AcOEt (3:1). The major fractions were concentrated to give 16.5 mg (40%) of **12b** and 22.6 mg (51% recovery) of recovered **10b**. **12b**: A colorless syrup, $[\alpha]_D^{25} + 73.9^\circ$ ($c=0.3$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.86 (3H, s, COCH_3), 3.40 (3H, s, OCH_3), 3.33—3.44 (2H, m, H-4, H-5), 3.45 (1H, dd, H-2), 3.72—3.85 (2H, m, H-3, H-6a), 3.98 (1H, dd, H-6b), 4.35 (1H, d, H-1), 4.62 (1H, dd, H-2'), 4.5—5.0 ($3 \times \text{PhCH}_2$), 4.88 (1H, ddd, H-5'), 5.00 (1H, d, H-1'), 5.60 (1H, dd, H-3'), 5.87 (1H, dd, H-4'), 6.47 (1H, d, NH); $J_{1,2}=3.5$, $J_{2,3}=9.0$, $J_{1',2'}=2.5$, $J_{2',\text{NH}}=9.5$, $J_{2',3'}=5.0$, $J_{3',4'}=3.5$, $J_{4',5'}=1.0$, $J_{5',6'a}=J_{5',6'b}=5.0$ Hz. FAB-MS m/z : 1002 ($\text{M} + \text{Na}^+$).

O³-(2-Acetamido-3,4,6-tri-O-benzoyl-2-deoxy- α -D-talopyranosyl)-N-benzoyloxycarbonyl-L-serine Benzyl Ester (12c) and O-(2-Acetamido-3,4,6-tri-O-benzoyl-2-deoxy- α -D-galactopyranosyl)-N-benzoyloxycarbonyl-L-serine Benzyl Ester (13) A solution of the *O*-glycosyl-L-serine ester **10c** (92.0 mg, 0.10 mmol) in dry THF (1.3 ml) was treated with 1 M $\text{BH}_3 \cdot \text{THF}$ complex (1.3 ml) as described for **12a**. After general work-up, purification on a silica-gel column with CHCl_3 -AcOEt (2:1) provided 17.7 mg (21%) of **12c** and 12.7 mg (15%) of **13** as a colorless syrup. **12c**: $[\alpha]_D^{25} + 66.5^\circ$ ($c=1.2$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.86 (3H, s, COCH_3), 4.03, 4.04 (1H each, dd, H-3), 4.26 (1H, dd, H-6'a), 4.42 (1H, ddd, H-5'), 4.56 (1H, ddd, H-2'), 4.58 (1H, dd, H-6'b), 4.63 (1H, ddd, H-2), 4.92 (1H, d, H-1'), 5.10, 5.24 (1H each, s, CH_2Ph), 5.48 (1H, dd, H-3'), 5.83 (1H, dd, H-4'), 5.84 (1H, d, NH-2), 6.45 (1H, d, NH-2'); $J_{1',2'}=2.0$, $J_{2',3'}=4.0$, $J_{3',4'}=3.0$, $J_{4',5'}=1.0$, $J_{5',6'a}=5.0$, $J_{5',6'b}=7.5$, $J_{2',\text{NH}}=9.0$, $J_{2,3a}=3.50$, $J_{2,3b}=5.0$, $J_{2,\text{NH}}=8.5$ Hz. $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 23.21 (COCH_3), 48.72 (C-2'), 54.39 (C-2), 62.59 (C-6'), 65.50 (C-3'), 67.16, 67.81 ($4 \times \text{CH}_2\text{Ph}$), 67.29 (C-5'), 68.33 (C-4'), 69.24 (C-3), 100.47 (C-1'), 164.67, 164.81, 165.99, 169.48, 169.52 ($5 \times \text{C}=\text{O}$). FAB-MS m/z : 845 (M^+), 867 ($\text{M} + \text{Na}^+$).

13: $[\alpha]_D^{25} + 42.3^\circ$ ($c=0.6$, CHCl_3). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.81 (3H, s, COCH_3), 3.98, 4.06 (1H each, dd, H-3), 4.28 (1H, dd, H-6'a), 4.36 (1H, ddd, H-5'), 4.51 (1H, dd, H-6'b), 4.64 (1H, ddd, H-2), 4.70, 5.12 (1H each, s, CH_2Ph), 4.85 (1H, ddd, H-2'), 4.98 (1H, d, H-1'), 5.42 (1H, dd, H-3'), 5.77 (1H, d, NH-2), 5.78 (1H, d, NH-2'), 5.81 (1H, dd, H-4'); $J_{1',2'}=4.0$, $J_{2',3'}=11.0$, $J_{3',4'}=3.0$, $J_{4',5'}=1.0$, $J_{5',6'a}=6.0$, $J_{5',6'b}=6.5$, $J_{6'a,6'b}=10.5$, $J_{2',\text{NH}}=9.0$, $J_{2,3a}=3.0$, $J_{2,3b}=3.5$, $J_{2,\text{NH}}=8.0$ Hz. $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 22.13 (COCH_3), 48.22 (C-2'), 54.48 (C-2), 62.59 (C-6'), 65.41, 67.33, 67.75 ($4 \times \text{CH}_2\text{Ph}$), 67.75 (C-5'), 68.19 (C-4'), 69.13 (C-3'), 69.49 (C-3), 99.15 (C-1'), 165.56, 165.99, 166.37, 170.14 ($5 \times \text{C}=\text{O}$). FAB-MS m/z : 845 (M^+), 867 ($\text{M} + \text{Na}^+$).

Acknowledgement The authors wish to thank Ms. Yohko Enomoto and Ms. Harumi Shimosato for assistance in some experiments. Financial support from the Japan Science Society is gratefully acknowledged.

References and Notes

- Crumpton M. J., *Nature* (London), **180**, 605 (1957).
- Heyworth R., Walker P. G., *Proc. Intern. Congr. Biochem.* 4th Vienna, **1**, 7 (1958).
- How M. J., Brimacombe J. S., Stacey M., *Adv. Carbohydr. Chem.*, **19**, 303 (1964); Jansson P.-E., Lindberg B., Lindquist U., *Carbohydr. Res.*, **140**, 101 (1985).
- Collins P. M., Overend W. G., *Chem. Ind.* (London), **1963**, 375; Brimacombe J. S., How M. J., *J. Chem. Soc.*, **1963**, 3886; Brimacombe J. S., Bryan J. G. H., Stacey M., *Carbohydr. Res.*, **1**, 258 (1965).
- Kaji E., Matsui E., Kobayashi M., Zen S., *Bull. Chem. Soc. Jpn.*, **68**, 1449 (1995).
- Kaji E., Anabuki N., Zen S., *Chem. Pharm. Bull.*, **43**, 1441 (1995).
- Kuhn R., Fischer H., *Justus Liebigs Ann. Chem.*, **612**, 65 (1958).
- Jeanloz R. W., Tarasiejska-Glazer Z., Jeanloz D. A., *J. Org. Chem.*, **26**, 532 (1961).
- Banaszek A., Karpiesiuk W., *Carbohydr. Res.*, **251**, 233 (1994).
- Lemieux R. U., Nagabhushan T. L., *Methods Carbohydr. Chem.*, **6**, 487 (1972).
- Stevens C. L., Bryant C. P., *Methods Carbohydr. Chem.*, **6**, 235 (1972).

- 12) Kaji E., Lichtenthaler F. W., *Trends Glycosci. Glycotechnol.*, **5**, 121 (1993) as a recent review concerned.
- 13) Kaji E., Lichtenthaler F. W., Osa Y., Takahashi K., Matsui E., Zen S., *Chem. Lett.*, **1992**, 707; Kaji E., Lichtenthaler F. W., Osa Y., Takahashi K., Zen S., *Bull. Chem. Soc. Jpn.*, **68**, 2401 (1995).
- 14) Ohle H., Behrend G., *Ber.*, **58**, 2585 (1925); available commercially from Aldrich Chemical Co. Inc.
- 15) Fugedi P., Liptak A., Nanasi P., *Carbohydr. Res.*, **104**, 55 (1982).
- 16) Baer E., Buchnea D., Stancer H. C., *J. Am. Chem. Soc.*, **81**, 2166 (1959).
- 17) Lichtenthaler F. W., Kaji E., Weprek S., *J. Org. Chem.*, **50**, 3505 (1985).
- 18) Lichtenthaler F. W., Kaji E., *Liebigs Ann. Chem.*, **1985**, 1659.
- 19) Kaji E., Lichtenthaler F. W., Osa Y., Zen S., *Bull. Chem. Soc. Jpn.*, **68**, 1172 (1995).
- 20) Erbing B., Lindberg B., Norberg T., *Acta Chem. Scand.*, **B32**, 308 (1978).